Physician profile
Ryan Patrick Nickerson
NPI 1578179503
$3,014.03
in general payments reported to CMS, 2019-2025
44 companies · $1,076 in 2025
The $1,076 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $96.01 · 2022: $235 · 2023: $895 · 2024: $712 · 2025: $1,076.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,588 · Education: $95.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,588.12 |
| Education | $95.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $315.92 | 2021-2025 | Darzalex, Tecvayli, Talvey |
| Abbvie INC. | $284.65 | 2023-2025 | |
| Astellas Pharma US INC | $248.10 | 2023-2025 | Xospata, Cresemba |
| Incyte Corporation | $208.88 | 2021-2025 | Jakafi, Monjuvi |
| Takeda Pharmaceuticals U.S.A., INC. | $144.19 | 2023-2025 | Iclusig, Livtencity, Ninlaro |
| Sobi, INC | $133.26 | 2024-2025 | |
| Beigene USA, INC. | $128.99 | 2023-2025 | Brukinsa |
| Pfizer INC. | $115.63 | 2023-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $94.38 | 2021-2023 | Imbruvica, Epkinly |
| Ipsen Biopharmaceuticals, INC | $92.68 | 2024-2025 | Tazverik |
| Genmab U.S., INC. | $80.83 | 2023-2024 | Epkinly |
| Daiichi Sankyo INC. | $79.83 | 2024-2025 | Vanflyta |
| Jazz Pharmaceuticals INC. | $78.96 | 2022-2024 | |
| Legend Biotech USA INC. | $67.78 | 2023-2024 | Carvykti |
| Celgene Corporation | $55.29 | 2022-2025 | Reblozyl |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Nickerson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.